Product
PD-1 Immune Checkpoint Inhibitor
1 clinical trial
2 indications
Indication
Nasopharyngeal CarcinomaIndication
Chemotherapy EffectClinical trial
PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab for Patients With Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: A Single Center, Single Arm, Phase II Clinical Study.Status: Active (not recruiting), Estimated PCD: 2023-01-04